A mixed-methods study of 456 people with depressive symptoms found that perceived need was a key predictor of professional ...
Dr. Penelope Markham, BioVie’s Senior Vice President and Program Lead for Long COVID, will share results from the Company’s Phase 2 ADDRESS-LC trial evaluating bezisterim for the treatment of the ...
IntroductionThe case study in this article can be tried as-is using "RxCode," an app for practicing with AI patients (free, ...
Alethios, the software platform delivering research infrastructure for human health, today launched a comprehensive suite of ...
Why can't the discernment of interviewers be verified?The task of reading through resumes is considered a burden for ...
As financial services scale their operations in cloud-native environments, the volume, complexity, and velocity of consumer ...
The 36-page report, released Tuesday, looks at how the province’s Department of Public Works decides what stretches of roads ...
According the the report, the province hasn't updated it's infrastructure deficit estimate since 2009.
BioVie Inc. announced the presentation of results from the Phase 2 ADDRESS-LC study (NCT06847191) evaluating bezisterim (NE3107) in patients with Long COVID at the 151st Annual Meeting of the American ...
In January 2026, Anthropic announced a new approach to AI safety. Rather than hard-coding a list of rules and decision ...
In AD, BioVie has conducted Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a ...
Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results